Doxorubicin and cisplatin regimen for high-grade osteosarcoma or Malignant Fibrous Histiocytoma (MFH) of the bone

Hospital Pharmacy

Volumn 42, Issue 7, 2007, Pages 605-616

  Rutledge, Matthew R ^d   Solimando Jr , Dominic A ^a   Waddell, J Aubrey ^b,c  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b Mechanical Aerospace and Biomedical Engineering The University of Tennessee (UTSI)   (United States)

^c BLOUNT MEMORIAL HOSPITAL   (United States)

^d MADIGAN ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOLASETRON MESILATE; DOXORUBICIN; GRANISETRON; METOCLOPRAMIDE; ONDANSETRON; PALONOSETRON; PROCHLORPERAZINE; PROMETHAZINE; SEROTONIN ANTAGONIST;

ACUTE KIDNEY TUBULE NECROSIS; ALLERGIC REACTION; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANEMIA; BLEEDING; CARDIOTOXICITY; CARDIOVASCULAR SYMPTOM; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; ERYTHEMA; EXTRAVASATION; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HEARING LOSS; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOLOGIC DISEASE; HUMAN; HYDRATION; HYPERSENSITIVITY REACTION; HYPERURICEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INFECTION; INJECTION SITE URTICARIA; KIDNEY FAILURE; KIDNEY INJURY; LEUKOPENIA; LIVER DISEASE; LIVER TOXICITY; LUNG TOXICITY; MALIGNANT FIBROUS HISTIOCYTOMA; METABOLIC DISORDER; MOUTH DISEASE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; OSTEOSARCOMA; OTOTOXICITY; PERIPHERAL NEUROPATHY; PRURITUS; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; TASTE DISORDER; TETANUS; TETANY; THROMBOCYTOPENIA; TINNITUS; VOMITING;

EID: 34547728138     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4207-605     Document Type: Review

References (32)

1. Souhami RL, Craft AW, Van der Eijken JW, et al. Randomized trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet. 1997;350:911-917.
2. Lewis IJ, Weedon S, Machin D, Stark D, Craft AW. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. J Clin Oncol. 2000; 18:4028-4037.
3. Bramwell VH, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992;10: 1579-1591.
4. Ordanel D, Souhami RL, Whelan J, et al. Doxorubicin and cisplatin with granulocyte colony-stimulating factor as adjuvant chemotherapy for osteosarcoma: phase II trial of the European Osteosarcoma Intergroup. J Clin Oncol. 1994;12:1842-1848.
5. Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histiologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007;99:112-128.
6. Ettinger LJ, Douglass HO Jr, Mindell ER, et al. Adjuvant adriamycin and cisplatin in newly diagnosed, nonmetastatic osteosarcoma of the extremity. J Clin Oncol. 1986;4:353-362.
7. Ettinger LJ, Douglass HO Jr, Higby DJ, et al. Adjuvant adriamycin and cis-diamminedichloroplatinum (cis-platinum) in primary osteosarcoma. Cancer. 1981;47:248-254.
8. Wilkins RM, Cullen JW, Camozzi AB, et al. Improved survival in primary nonmetastatic pediatric osteosarcoma of the extremity. Clin Orthop Relat Res. 2005;438:128-136.
9. Malawer M, Buch R, Reaman G, et al. Impact of two cycles of preoperative chemotherapy with intraarterial cisplatin and intravenous doxorubicin on the choice of surgical procedure for high-grade bone sarcomas of the extremities. Clin Ortho Relat Res. 1991;270:214-222.
10. Hughes BG, Woodward N, Lourigan KJ, et al. Adjuvant chemotherapy for osteogenic sarcoma: long term follow-up from a single institution. (abstract 9071). Available at: http://www.asco.org/portal/site/ASCO/menuitem. 34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID= 34&abstractID=31564. Accessed May 1, 2007.
11. Bramwell VHC, Steward WP, Nooij M, et al. Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: a European Osteosarcoma Intergroup study. J Clin Oncol. 1999;17:3260-3269.
12. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15:103-109.
13. National Comprehensive Cancer Network. NCCN antiemesis practice guidelines. Available at: http://www.nccn.org/professionals/physician_gls/PDF/ antiemesis.pdf. Accessed May 1, 2007.
14. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24:2932-2947.
15. Multinational Association for Supportive Care in Cancer. Antiemetic Guidelines. 2007. Available at: http://www.mascc.org/media/Resource_centers/ MASCC_Guidelines_Updatepdf. Accessed May 1, 2007.
16. Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23:1289-1294.
17. Terrey JP, Aapro MS. The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res. 1996;8:281-288.
18. Carmichael J, Keizer HJ, Cupissol D, Milliez J, Scheidel P, Schindler AE. Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs. 1998;9:381-385.
19. de Wit R, de Boer AC, vd Linden GH, Stoter G, Sparreboom A, Verweij J. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer. 2001;85:1099-1101.
20. Smith IE. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol. 1993;119:350-354.
21. Soukop M. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer. 1994;2:177-183.
22. Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol. 1985;3:1379-1384.
23. Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol. 1993;50:147-158.
24. Kintzel PE. Anticancer drug-induced kidney disorders - incidence, prevention and management. Drug Saf. 2001;24:19-38.
25. Weiss RB. Hypersensitivity reactions. Semin Oncol. 1992;19:458-477
26. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187-3205.
27. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - Myeloid Growth Factors. v.1.2006. Available at: http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf. Accessed May 2, 2007.
28. Larson DL. Treatment of tissue extravasation by antitumor agents. Cancer. 1982;49:1796-1799.
29. Larson DL. What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg. 1985;75:397-402.
30. Mullin S, Beckwith MC, Tyler LS. Prevention and management of antineoplastic extravasation injury. Hosp Pharm. 2000;35:57-74.
31. Floyd J, Mirza I, Sachs, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol. 2006;33:50-67.
32. Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev. 1995;21:33-64.